Every material Form 8-K Humacyte, Inc. has filed with the SEC since July 31, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Humacyte appointed two new directors, Scott Coward and Paul Kuznik, effective September 22, 2026, and announced the appointments in a September 28, 2026 press release. Mr. Coward joins the Audit Committee and Mr. Kuznik joins the Commercial Committee, and both will receive standard non-employee director compensation. The filing reports no financial results and no change in management roles, so the change has limited direct impact on shareholders.
Scott Coward appointed Class I director with a term expiring in 2028; former Exact Sciences executive and board member
Paul Kuznik appointed Class II director with a term expiring in 2029; former CEO of Bolton Medical
Each director receives a $50,000 annual cash retainer, $5,000 per year for committee service, and an option to purchase 125,000 shares of common stock
Humacyte reported second quarter 2026 total revenue of $0.4 million, up from $0.3 million a year earlier, and a net loss of $36.8 million, compared with $37.7 million in the prior-year quarter. For the six months, the company swung to a net loss of $54.4 million from net income of $1.5 million, mainly due to a non-cash remeasurement of its contingent earnout liability, which matters for shareholders because it shows how non-operating accounting items can outweigh operating results.
Q2 2026 total revenue was $0.4 million versus $0.3 million in Q2 2025; contract revenue was zero after a prior-year research collaboration ended.
Q2 2026 net loss was $36.8 million ($0.16 per share) versus $37.7 million ($0.24 per share) a year earlier.
Six-month net loss was $54.4 million, compared with net income of $1.5 million in the first six months of 2025, driven by the non-cash remeasurement of the contingent earnout liability.
Cash, cash equivalents and restricted cash were $80.3 million at June 30, 2026, after a June 2026 public offering that raised gross proceeds of $57.5 million.
Humacyte received a Nasdaq notice that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days ended July 30, 2026. The company has 180 calendar days, until January 27, 2027, to regain compliance, which requires a closing bid of $1.00 or more for at least 10 consecutive business days. Nasdaq says the notice has no immediate effect on the stock's listing, but the company cannot assure it will regain compliance.
Notice received July 31, 2026, for 30 consecutive business days ended July 30, 2026 below $1.00 bid price
Compliance period runs until January 27, 2027 (180 calendar days)
Regaining compliance requires closing bid of $1.00 or more for at least 10 consecutive business days
Stock continues to trade on The Nasdaq Global Select Market under HUMA
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Humacyte, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →